Sun Pharma Advanced Research Company Q2 loss widens to Rs 63 cr
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Monday reported a net loss of Rs 63.16 crore for the quarter ended September 30 of the ongoing fiscal. The company had reported a loss of Rs 2.58 crore for July-September, 2018-19.
Total income declined to Rs 19.45 crore during the second quarter as compared with Rs 65.92 crore in the year-ago period, SPARC said in a regulatory filing.
Read Also: FIRST: Sun Pharma unveils dry-eye treatment drug CEQUA in US
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd